Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts

Digestive and Liver Disease

Volumn 35, Issue 8, 2003, Pages 523-528

  Parente, Fabrizio ^a   Cucino, C ^a   Bianchi Porro, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Proton pump inhibitor based triple therapies; Quadruple therapy; Ranitidine bismuthate; Refractory Helicobacter pylori infection; Rifabutin based triple therapies

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; BISMUTH SALICYLATE; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; BISMUTH; DRUG DERIVATIVE; PROTON PUMP; RANITIDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; BONE MARROW TOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; ERADICATION THERAPY; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LEUKOPENIA; MAINTENANCE THERAPY; PATIENT COMPLIANCE; RISK FACTOR; SALVAGE THERAPY; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG COMBINATION; MULTIDRUG RESISTANCE; REVIEW;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; PROTON PUMPS; RANITIDINE;

EID: 2142751121     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00268-8     Document Type: Article

References (53)

1. Peura DA. The report of the Digestive Health Initiative. International Update Conference on Helicobacter pylori. Gastroenterology 1997;113:S4-8.
2. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
3. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
4. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2330-8.
5. Caselli M, Parente F, Palli D, Covacci A, Alvisi V, Gasbarrini G, et al. Cervia working group report: guidelines on the diagnosis and treatment of Helicobacter pylori infection. Dig Liver Dis 2001;33:75-80.
6. Huang J-Q, Chiba N, Wilkinson JM, Hunt RH. Which combination therapy can eradicate >90% of Helicobacter pylori infection? A meta-analysis of amoxicillin, metronidazole, tetracycline, and clarithromycin containing regimens. Gastroenterology 1997;112:A19.
7. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999;13:489-96.
8. De Boer WA, Tytgat GNJ. Treatment of Helicobacter pylori infection. Br Med J 2000;320:31-4.
9. Graham DY, de Boer WA, Tytgat GNJ. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072-6.
10. Peitz U, Sulliga M, Wolle K, Leodolter A, Von Armin U, Kahl S, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure H. pylori infection: impact of two second-line therapies in a randomised study. Aliment Pharmacol Ther 2002;16:315-24.
11. Pilotto A, Franceschi M, Rassu M, Leandro G, Bozzola L, Furlan F, et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failure after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis 2000;32:667-72.
12. Parente F, Maconi G, Bianchi Porro G, Caselli M. Stool test with polyclonal antibodies for monitoring Helicobacter pylori eradication in adults: a critical reappraisal. Scand J Gastroenterol 2002;37:747-9.
13. Megraud F, Burette A, Glupczynski Y, Fiocca R, Logan R, Quina M, et al. Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi-centre study using centralized facility testing. Eur J Gastroenterol Hepatol 2000;12:629-33.
14. Graham DY, Lew GM, Malaty HM, Evans DG, Evans Jr. DJ, Klein PD, et al. Factors influencing the eradication of H .pylori with triple therapy. Gastroenterology 1992;102:493-6.
15. Cutler AF, Schubert TT. Patient factors affecting H. pylori eradication with triple therapy. Am J Gastroenterol 1993;88:505-9.
16. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxycillin for cure of Helicobacter pylori infection: factors influencing the treatment success. Scand J Gastroenterol 1994;29:1070-5.
17. Moayyedi P, Chalmers DM, Axon AT. Patient factors that predict failure of omeprazole, clarythromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1997;32:24-7.
18. Fallone CA, Loo V, Joseph L, Barkun J, Kostyk R, Barkun AN. Predictors of failure of Helicobacter pylori eradication and predictors of ulcer recurrence: a randomised controlled trial. Clin Invest Med 1999;22:185-94.
19. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001;15:1023-9.
20. Leeds Help Study Group, Moayyedi P, Feltbower R, Crocombe W, Mason S, Atha P, Brown J, et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Aliment Pharmacol Ther 2000;14:719-28.
21. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi Porro G. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001;96:359-66.
22. Houben MH, Van De Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GNJ. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistances on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55.
23. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-57.
24. Nagahara A, Miwa H, Okura R, Yamada T, Sato K, Hojo M, et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001;16:613-8.
25. Beales IL. Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol 2001;1:7.
26. Gisbert JP, Boixeda D, Bermejo F, Niebes Rincon M, Jesus Higes M, Angeles Arpa M, et al. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999;11:1049-54.
27. Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001;96:1335-9.
28. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment Pharmacol Ther 2001;15:1017-22.
29. Gomollon F, Ducons JA, Ferrero M, Garcia Cabezudo J, Guirao R, Simon MA, et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999;4:222-5.
30. Gasbarrini A, Ojetti V, Pitocco D, Armuzzi A, Silveri NG, Pola P, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000;35:260-3.
31. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999;13:489-96.
32. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day rescue therapy after Helicobacter pylori treatment failure: omeprazole, bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999;13:1311-6.
33. Perri F, Festa V, Clemente R, Villanbi MR, Quitadamo M, Caruso N, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
34. Michopoulos S, Tsibouris P, Bouzakis H, Balta A, Vougadiotis J, Broutet N, et al. Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000;14:737-44.
35. Boixeda D, Bermejo F, Martin-De-Argila C, Lopez-Sanroman A, Defarges V, Hernandez-Ranz F, et al. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidaazole as rescue treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16:1457-60.
36. Georgopoulos SD, Ladas SD, Karatapanis S, Triantafyllou K, Spiliadi C, Mentis A, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002;16:569-75.
37. Reilly TG, Ayres RC, Poxon V, Walt RP. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995;9:483-90.
38. Lerang F, Moum B, Haug JB, Berge T, Tolas P, Sandvei PK, et al. Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy. Scand J Gastroenterol 1997;32:1209-14.
39. Magaret N, Burm M, Faigel D, Kelly D, Peterson W, Fennerty MB. A randomised trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001;19:174-8.
40. Labenz J, Beker JA, Dekker CP, Farley A, Klor HU, Jonsonn A. Doubling the omeprazole dose (40 mg bd vs. 20 bd) in dual therapy with amoxicillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1997;11:515-22.
41. Miehlke S, Kirsch C, Ochsenkuhn T, Vieth M, Haferland C, Ziegler K, et al. High-dose omeprazole/amoxicillin therapy versus quadruple therapy for treatment of Helicobacter pylori resistant against both metronidazole and clarithromycin - a prospective, randomized cross-over study. Gastroenterology 2001;120:A120.
42. Moayyedi P, Tompkins DS, Barrowclough S, Pearson J, Axon AT. Outcome of Helicobacter pylori eradication in omeprazole, clarithromycin and tinidazole treatment failures. Gut 1995;37(Suppl 2):T125.
43. Moayyedi P. Amoxycillin dual therapy against Helicobacter pylori - the final nail in the coffin? Dig Liver Dis 1997;29:506-8.
44. Zullo A, Hassan C, Campo SM, Lorenzetti R, Febbraio I, De Mattheis M, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001;15:1193-7.
45. Perri F, Festa V, Clemente R, Quitadamo M, Adriulli A. Rifabutin-based rescue therapy for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-6.
46. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000;31:222-5.
47. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication rescue therapy. Aliment Pharmacol Ther 2001;15:143.
48. Wong WM, Wong BC, Lu H, Gu Q, Yin Y, Wang WH, et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapy. Aliment Pharmacol Ther 2002;16:793-8.
49. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002;7:225-31.
50. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, et al. Efficacy of two 1-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-43.
51. Tucci A, Poli L, Caletti G. Treatment of 'ineradicable' Helicobacter pylori infection. Am J Gastroenterol 1999;94:1713-5.
52. Cremonini F, Canducci F, Di Caro S, Santarelli L, Armuzzi A, Gasbarrini G, et al. Helicobacter pylori treatment: a role for probiotics? Dig Dis 2001;19:144-7.
53. Mysore JV, Wigginton T, Simon PM, Zopf D, Heman-Ackah LM, Dubois A. Treatment of Helicobacter pylori infection in Rhesus monkeys using a novel anti-adhesion compound. Gastroenterology 1999;117:1316-25.